Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy

NCT04680065 is registered in ClinicalTrials.gov with Brain Neurotherapy Bio, Inc. as lead sponsor.

NCT NCT04680065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04680065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy
Lead sponsor
Brain Neurotherapy Bio, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 3, 2023
Completion date
August 31, 2028
Enrollment
9 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy